SRPT (STOCKS)
Sarepta Therapeutics,, Inc. Common Stock
$18.350000
-0.030000 (-0.16%)
Prev close: $18.380000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Michael E. Severino
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $2,251.95M
- Employees
- 1,372
- P/E (TTM)
- -6.36
- P/B (TTM)
- 1.27
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
8
Strong Buy
6
Buy
13
Hold
5
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-0.05 | $0.26 | -0.3125 | -119.05% |
|
Mar 2026 (Q1)
|
$2.88 | $1.01 | +1.8683 | +184.67% |
|
Dec 2025 (Q4)
|
$-3.93 | $-1.26 | -2.6746 | -213.05% |
|
Sep 2025 (Q3)
|
$-0.01 | $-0.83 | +0.8217 | +98.80% |
Financial Statements
| Revenues | $1.97B |
| Benefits Costs and Expenses | $790.63M |
| Costs And Expenses | $1.26B |
| Nonoperating Income/Loss | $12.33M |
| Operating Expenses | $2.09B |
| Selling, General, and Administrative Expenses | $436.74M |
| Other Operating Expenses | $1.66B |
| Operating Income/Loss | -$143.25M |
| Income/Loss From Continuing Operations After Tax | -$136.73M |
| Income/Loss From Continuing Operations Before Tax | $590.31M |
| Income Tax Expense/Benefit | $5.81M |
| Interest Expense, Operating | -$81.36M |
| Net Income/Loss | -$136.73M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$136.73M |
| Net Income/Loss Available To Common Stockholders, Basic | -$136.73M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$1.33 |
| Diluted Earnings Per Share | -$1.44 |
| Basic Average Shares | 207,023,000 |
| Diluted Average Shares | 224,072,000 |
| Assets | $3.19B |
| Current Assets | $2.22B |
| Inventory | $904.27M |
| Other Current Assets | $1.32B |
| Noncurrent Assets | $964.69M |
| Fixed Assets | $325.99M |
| Other Non-current Assets | $638.70M |
| Liabilities | $1.66B |
| Current Liabilities | $502.91M |
| Accounts Payable | $50.98M |
| Wages | $40.97M |
| Other Current Liabilities | $410.95M |
| Noncurrent Liabilities | $1.16B |
| Long-term Debt | $847.62M |
| Other Non-current Liabilities | $310.18M |
| Equity | $1.53B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $1.53B |
| Liabilities And Equity | $3.19B |
| Net Cash Flow From Operating Activities | $111.01M |
| Net Cash Flow From Operating Activities, Continuing | $111.01M |
| Net Cash Flow From Investing Activities | $100.85M |
| Net Cash Flow From Investing Activities, Continuing | $100.85M |
| Net Cash Flow From Financing Activities | -$156.76M |
| Net Cash Flow From Financing Activities, Continuing | -$156.76M |
| Net Cash Flow | $55.10M |
| Net Cash Flow, Continuing | $55.10M |
| Comprehensive Income/Loss | -$137.56M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$266.67M |
| Other Comprehensive Income/Loss | -$566.00K |